Results 151 to 160 of about 1,795 (205)
Some of the next articles are maybe not open access.

Related searches:

Odanacatib Pharmacokinetics Comparison Between Chinese and Non‐Chinese Postmenopausal Women

Clinical Pharmacology in Drug Development, 2018
AbstractOdanacatib (ODN), an oral selective inhibitor of cathepsin K, was an investigational agent previously in development for the treatment of osteoporosis. In this phase 1 open‐label study, 12 healthy Chinese postmenopausal women received single‐dose ODN 50 mg on day 1 and multiple‐dose ODN 50 mg once weekly on days 15, 22, 29, and 36 under fasted ...
Xia Chen   +9 more
semanticscholar   +3 more sources

Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects

The Journal of Clinical Pharmacology, 2017
AbstractThis open‐label 2‐period study assessed the effect of multiple‐dose administration of rifampin, a strong cytochrome P450 3A (CYP3A) and P‐glycoprotein inducer, on the pharmacokinetics of odanacatib, a cathepsin K inhibitor. In period 1, 12 healthy male subjects (mean age, 30 years) received a single dose of odanacatib 50 mg on day 1, followed ...
S. Stoch   +11 more
semanticscholar   +3 more sources

Asymmetric hydrogenation of trifluoromethyl ketones: application in the synthesis of Odanacatib and LX-1031

, 2021
The asymmetric hydrogenation of trifluoromethyl ketones via iridium catalysis to access chiral secondary 2,2,2-trifluoroethanols is presented. The key intermediates of Odanacatib and LX1301 were prepared with high yields and enantioselectivities.
Tiaozhen Zhu, Pan‐Lin Shao, Xumu Zhang
semanticscholar   +1 more source

Odanacatib for the treatment of osteoporosis

Expert Opinion on Pharmacotherapy, 2015
Osteoporosis and fragility fractures are important public health concerns. Cathepsin K inhibitors, including odanacatib , are a novel class of medications for osteoporosis whose mechanism of action is to directly inhibit bone resorption without killing osteoclasts, thereby permitting the complex coupling between bone resorption and formation to ...
Miranda K, Boggild   +6 more
openaire   +2 more sources

Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer.

Biomaterials
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) demonstrates unique characteristics in anticancer therapies as it selectively induces apoptosis in cancer cells. However, most cancer cells are TRAIL-resistant. Odanacatib (ODN), a cathepsin K inhibitor, is considered a novel sensitizer for cancer treatment.
Thoa Thi Kim Nguyen   +9 more
semanticscholar   +4 more sources

Home - About - Disclaimer - Privacy